Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 40 entries
View as:

Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.

Phase: N/A Priority: Normal
NCT ID: NCT06643897 Org: User:
Start: 07/16/24 End: 10/23/24 Due: 10/23/25

Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel

Phase: N/A Priority: Normal
NCT ID: NCT04466462 Org: User:
Start: 05/26/20 End: 06/30/20 Due: 06/30/21

Repurposing Clinically Approved Drugs for Yaws with an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

Phase: N/A Priority: Normal
NCT ID: NCT05764876 Org: User:
Start: 03/14/23 End: 12/01/24 Due: 12/01/25

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT02818348 Org: User:
Start: 06/30/16 End: 11/23/16 Due: 11/23/17

Supervised Computerized Active Program for People With Post-COVID Syndrome (SuperCAP Study)

Phase: N/A Priority: Normal
NCT ID: NCT06315894 Org: User:
Start: 10/03/24 End: 09/03/25 Due: 09/03/26

Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)

Phase: N/A Priority: Normal
NCT ID: NCT04385875 Org: User:
Start: 06/01/20 End: 02/10/22 Due: 02/10/23

Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

Phase: N/A Priority: Normal
NCT ID: NCT04621123 Org: User:
Start: 11/10/20 End: 07/28/21 Due: 07/28/22

Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study

Phase: N/A Priority: Normal
NCT ID: NCT01348282 Org: User:
Start: 05/31/11 End: 03/31/14 Due: 03/31/15

Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Phase: N/A Priority: Normal
NCT ID: NCT02577042 Org: User:
Start: 10/15/15 End: 06/04/18 Due: 06/04/19

Incidence of Infection Reported by COVID-19 in Attendees of a Commercial Music Concert

Phase: N/A Priority: Normal
NCT ID: NCT04824625 Org: User:
Start: 03/27/21 End: 04/10/21 Due: 04/10/22

Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01346878 Org: User:
Start: 07/31/10 End: 04/30/12 Due: 04/30/13

Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures

Phase: N/A Priority: Normal
NCT ID: NCT04668625 Org: User:
Start: 11/30/20 End: 01/08/21 Due: 01/08/22

Rapid Screening Circuit of COVID 19 in Schools, Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT04878809 Org: User:
Start: 04/22/21 End: 06/17/21 Due: 06/17/22

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

Phase: N/A Priority: Normal
NCT ID: NCT03029689 Org: User:
Start: 07/28/17 End: 04/30/20 Due: 04/30/21

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT07028385 Org: User:
Start: 06/30/25 End: 04/30/26 Due: 04/30/27

Break-through Infection Following Mpox vaccinatIon

Phase: N/A Priority: Normal
NCT ID: NCT05522296 Org: User:
Start: 09/12/22 End: 03/30/24 Due: 03/30/25

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

Phase: N/A Priority: Normal
NCT ID: NCT04689737 Org: User:
Start: 03/20/21 End: 06/14/21 Due: 06/14/22

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01719627 Org: User:
Start: 10/31/12 End: 01/31/15 Due: 01/31/16

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

Phase: N/A Priority: Normal
NCT ID: NCT04097925 Org: User:
Start: 02/18/20 End: 08/24/20 Due: 08/24/21

Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

Phase: N/A Priority: Normal
NCT ID: NCT01378910 Org: User:
Start: 06/30/11 End: 05/31/14 Due: 05/31/15

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Phase: N/A Priority: Normal
NCT ID: NCT06607588 Org: User:
Start: 10/25/24 End: 09/30/26 Due: 09/30/27

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

Phase: N/A Priority: Normal
NCT ID: NCT04079452 Org: User:
Start: 02/18/20 End: 08/31/20 Due: 08/31/21

Drug Interactions Between Silimarine and Darunavir/Ritonavir

Phase: N/A Priority: Normal
NCT ID: NCT01346982 Org: User:
Start: 03/31/11 End: 07/31/11 Due: 07/31/12

Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study

Phase: N/A Priority: Normal
NCT ID: NCT03835546 Org: User:
Start: 10/26/15 End: 06/29/18 Due: 06/29/19

Drug Interactions Between Echinacea Purpurea and Etravirine

Phase: N/A Priority: Normal
NCT ID: NCT01347658 Org: User:
Start: 04/30/11 End: 08/31/11 Due: 08/31/12